©2022 Stanford Medicine
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Not Recruiting
Trial ID: NCT00724334
Purpose
The purpose of this study is to evaluate the long-term effects of orally administered
SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001
study.
Official Title
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Stanford Investigator(s)
Jason Gotlib
Professor of Medicine (Hematology)
Eligibility
Inclusion Criteria:
- Completion of MF-TG101348-001 study
- Diagnosis of myelofibrosis
- At least 18 years of age
Exclusion Criteria:
- Any acute or chronic medical abnormality that may increase the risk associated with
study participation
Intervention(s):
drug: SAR302503 (TG101348)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061